Crescendo widens pivotal solid tumour therapy trial
The CB307 study expansion involves the addition of a new pembrolizumab combination cohort
Read More
Tag: crescendo
Crescendo links with CRUK to progress cancer therapy
The charity’s Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213
Read More
Takeda to evaluate Crescendo Biologics’ Humabodies
Crescendo Biologics has announced that Takeda is planning to evaluate the application of its recently licensed Humabodies, for the development of novel CAR-T therapeutics.
Read More
Takeda licenses Crescendo’s Humabodies
Japanese drug giant Takeda has taken an exclusive license to Cambridge, UK-based Crescendo Biologics’ Humabodies directed to one of its oncology targets.
Read More
UK’s Crescendo seals $790m Takeda deal
Takeda and Crescendo Biologics have signed a cancer drug development pact potentially worth nearly $800 million.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
